Navigation Links
Watson to Host Conference Call and Webcast to Discuss Second Quarter 2010 Earnings
Date:7/8/2010

MORRISTOWN, N.J., July 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the Company intends to release its second quarter 2010 financial results on Thursday, August 5, 2010 prior to the open of the U.S. financial markets.  The Company will also host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on August 5, 2010 to discuss its financial results and provide an update on the Company's outlook for 2010.  The dial-in number to access the call is (877) 251-7980, or from international locations, (706) 643-1573.

A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 12:00 midnight Eastern Daylight Time on August 15, 2010.  The replay may be accessed by dialing (800) 642-1687 and entering pass code 84949830.  From international locations, the replay may be accessed by dialing (706) 645-9291 and entering the same pass code.  To access the webcast, go to Watson's Investor Relations Web site at http://ir.watson.com.  A replay of the webcast will also be available.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on urology and women's health. Watson has operations in many of the world's established and growing international markets.

For press releases and other company information, visit the Watson Web site at http://www.watson.com

(Logo:  http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017  Ablation is the ... a wide range of purposes, from cancerous or ... conducting cardiac tissue in atrial fibrillation and others. ... pushing the researchers to innovate and improvise existing ... The ablation device global market is expected to ...
(Date:3/22/2017)... 2017  Applied BioMath ( www.appliedbiomath.com ), the ... and development, today announced the latest line-up of ... is a day full of presentations, posters, and ... community. The focus is to learn about how ... drug research and development. The event ...
(Date:3/22/2017)... A new independent study demonstrates that ... ultraviolet-C (UV-C) disinfection solution of choice for combating ... Published in the March issue of the ... peer-reviewed study of UV-C disinfection systems detailed the ... and Rochester General Hospital. According to the study, ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... 2017 , ... An intensive search of the medical literature has revealed no ... PhD. He says investigating this possibility, is important because Miami-Dade in 2016 ... infections with HIV. , His findings appear on Analizir.com. . Dr. ...
(Date:3/22/2017)... ... March 22, 2017 , ... Intrinsic Imaging, LLC, an ... and operational excellence in oncology clinical trials, proudly announces today that it has ... non-small cell lung cancer and small cell lung cancer. , Throughout this trial, ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... services to regional families and business owners, is joining the Teen Recovery Solutions ... in the area. , A growing number of Oklahoma teens and adolescents face ...
(Date:3/22/2017)... ... 22, 2017 , ... College basketball surges to its peak during the March ... that is, recruiting people to be foster parents. Through a televised spot, Coach Self ... foster care due to abuse, neglect and other family challenges. People who respond to ...
(Date:3/22/2017)... ... 2017 , ... Nearly a decade after it was first recommended that men ... screening continues to stir controversy. The US Preventative Services Task Force (USPSTF) issued a ... benefits. Now, news from a study published in JAMA Oncology suggests that ...
Breaking Medicine News(10 mins):